Immunocore Holdings plc American Depositary Shares (IMCR)

The article highlights three low-cost stocks with potential significant growth: a gold mining company, a footwear retailer, and a biotechnology firm developing cancer treatments, each with unique market opportunities and analyst perspectives.

Immunocore Plc reported Q2 2025 results with 30% revenue growth to $98.0 million, driven by KIMMTRAK sales. Despite revenue success, the company experienced a net loss and continued investing heavily in research and development across multiple clinical programs.

Immunocore's HIV functional cure candidate IMC-M113V showed promising safety and signals of dose-dependent viral control in a Phase 1/2 trial, with some patients maintaining viral suppression for up to 12 weeks after stopping antiretroviral treatment.

14 analysts have shared their evaluations of Immunocore Hldgs (NASDAQ:IMCR) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somew...

Sarepta (SRPT) announces the FDA's acceptance of its efficacy supplement to the Elevidys BLA, seeking to expand the treatment label for its DMD drug. The stock gains 8%.